Evotec Achieves Milestone in Medicinal Chemistry Collaboration with
Ono Pharmaceutical Co., Ltd.
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ - Evotec receives milestone from Ono for the progression of novelprotease inhibitors into lead optimisation -Hamburg, Germany / Abingdon, UK - 14 December 2009: Evotec AG(Frankfurt Stock Exchange: EVT, TecDAX) today announced that it hasreceived a milestone payment from Ono Pharmaceutical Co., Ltd. (Ono)from its research collaboration aimed at identifying novel inhibitorsfor a protease target. The milestone is received for the progressionof the medicinal chemistry collaboration into lead optimisation. Theprogramme success validates again the strength of Evotec's FragmentBased Drug Discovery platform, EVOlutionTM, along with its integrateddrug discovery capabilities, including biology, medicinal chemistry,structure based drug design and in vitro pharmacology.Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Weare delighted to have achieved this important milestone with Ono andonce again to demonstrate the value that we bring to our partnershipwith them. The success of this project is a testament to the strongpartnership between our two companies and we look forward tocontinuing working closely with our colleagues at Ono both on thisprogramme as it progresses to the clinic as quickly as possible andalso on our recently initiated collaboration on a second target asproactively as possible.""We have a high regard for Evotec's drug discovery expertise and thecapabilities and technologies used in progressing this collaboration.The achievement of this milestone further validates our strategy towork with the best collaborators in the industry. We look forward toreaching additional milestones together as our programmes progress",said Kazuhito Kawabata, Ph.D., Managing Director, Head of ResearchHeadquarters and Director of Minase Research Institute at Ono.Evotec and Ono are also collaborating on a second target, an ionchannel, for which Ono will access Evotec's ion channel drugdiscovery platform and expertise. For this second programme Evotecwill receive further research funding and milestone payments.Contact Evotec AG:Dr Werner Lanthaler, Chief Executive Officer, Phone:+49.(0)40.56081-242, werner.lanthaler(at)evotec.comForward-looking statementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programmes and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures and may not recognize the results of suchmeasures within the expected timeframe; risks that product candidatesmay fail in the clinic or may not be successfully marketed ormanufactured; the risk that we will not achieve the anticipatedbenefits of our collaborations, partnerships and acquisitions in thetimeframes expected, or at all; risks relating to our ability toadvance the development of product candidates currently in thepipeline or in clinical trials; our inability to further identify,develop and achieve commercial success for new products andtechnologies; the risk that competing products may be moresuccessful; our inability to interest potential partners in ourtechnologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based.http://hugin.info/131215/R/1360892/332248.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Bereitgestellt von Benutzer: hugin
" alt="Heatherdale Resources Ltd.: New High-Grade Discovery Expanded at NiblackDatum: 14.12.2009 - 07:59 Uhr
Sprache: Deutsch
News-ID 9564
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 473 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Achieves Milestone in Medicinal Chemistry Collaboration with
Ono Pharmaceutical Co., Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
